Hariharan Ramesh
Research Subjects
Hariharan Ramesh has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
V. Lekha
Digestive Diseases Center, Lakeshore Hospitals, Cochin, India
5 shared publicationsA. Venugopal
Digestive Diseases Center, Lakeshore Hospitals, Cochin, India
4 shared publicationsA Venugopal
3 shared publicationsG. Jacob
Digestive Diseases Center, Lakeshore Hospitals, Cochin, India
3 shared publicationsGeorge Jacob
Department of Gastrointestinal Surgery, Lakeshore Hospital, Cochin, India
3 shared publicationsB. Venugopal
Department of Gastrointestinal Surgery, PVS Memorial Hospital, 31/543, Subhash Nagar, Edappally, Cochin 682024, Kerala, India
2 shared publications
Latest Publications
- 17 March 2013
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 32 (2) , 80-81
Palliation of jaundice in pancreatic cancer: stent or surgery?
- 17 March 2013
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 32 (2) , 80-81
Palliation of jaundice in pancreatic cancer: stent or surgery?
- 1 August 2010
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 72 (4) , 285-289
Management of Pancreatic Cancer: Current Status and Future Directions
Pancreatic ductal adenocarcinoma has a dismal prognosis, despite advances in surgery, and adjuvant therapy. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline respectability. Extended lymphadenectomy has no role in improving survival, but may worsen quality of life. Venous resection can be performed if it helps to achieve an R0 resection, but arterial resection is not justified. A host of newer agents, both cytotoxic and targeted, are being evaluated. The article summarizes the critical issues and looks ahead to the future.
- 1 August 2010
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 72 (4) , 285-289
Management of Pancreatic Cancer: Current Status and Future Directions
Pancreatic ductal adenocarcinoma has a dismal prognosis, despite advances in surgery, and adjuvant therapy. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline respectability. Extended lymphadenectomy has no role in improving survival, but may worsen quality of life. Venous resection can be performed if it helps to achieve an R0 resection, but arterial resection is not justified. A host of newer agents, both cytotoxic and targeted, are being evaluated. The article summarizes the critical issues and looks ahead to the future.
- 1 December 2009
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 71 (6) , 368-372
Management of pancreatic cancer: Current status and future directions
Despite advances in surgery and adjuvant therapy pancreatic ductal adenocarcinoma has a dismal prognosis. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline resectability. Extended lymphadenectomy has no role in improving survival, but may worsen quality of life. Venous resection can be performed if it helps to achieve an R0 resection, but arterial resection is not justified. A host of newer agents, both cytotoxic and targeted, are being evaluated. The article summarizes the critical issues and looks ahead to the future.
- 1 December 2009
- Published by Springer Nature in Indian Journal of Surgery
- Vol. 71 (6) , 368-372
Management of pancreatic cancer: Current status and future directions
Despite advances in surgery and adjuvant therapy pancreatic ductal adenocarcinoma has a dismal prognosis. Surgical resection with negative margins remains the mainstay of treatment, and results can be improved with neoadjuvant therapy when the lesion is of borderline resectability. Extended lymphadenectomy has no role in improving survival, but may worsen quality of life. Venous resection can be performed if it helps to achieve an R0 resection, but arterial resection is not justified. A host of newer agents, both cytotoxic and targeted, are being evaluated. The article summarizes the critical issues and looks ahead to the future.
- 20 February 2009
- Published by Wiley in World Journal of Surgery
- Vol. 33 (5) , 1107
T Tubes in Intestinal Perforations in Children
- 20 February 2009
- Published by Wiley in World Journal of Surgery
- Vol. 33 (5) , 1107
T Tubes in Intestinal Perforations in Children
- 1 January 2009
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 28 (1) , 24-27
CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Background The role of the tumor marker CA 19-9 in differentiating benign from malignant masses in chronic pancreatitis has not been extensively studied. Aim This study aims at assessing the accuracy of CA 19-9 in differentiating inflammatory head masses in chronic pancreatitis from superimposed carcinomas on chronic pancreatitis. Methods The data of 84 consecutive patients who had mass lesions in chronic pancreatitis were analyzed to determine the sensitivity, specificity and predictive values at cut-off values of 37, 100, 200 and 300 U/mL. Receiver operating characteristic (ROC) curves were used to assess the sensitivity and specificity. Results There were 50 benign masses and 34 malignancies. The overall sensitivity and specificity of CA 19-9 for cancer was 68% and 70%, respectively. There was a higher positivity of CA 19-9 in cancers than in benign masses (23/34; 68% versus 15/50; 30%, P<0.01) with cut-off values of 37 U/mL. Higher positivity rates were obtained in cancers using other cut-off values such as 100, 200 and 300 U/mL. Values over 300 U/mL were 100% specific for malignancy, but occurred in only 5 (of whom had distant metastases) of 34 patients. Conclusion CA 19-9 level in excess of 300 U/mL in mass lesions in chronic pancreatitis was always indicative of malignancy.
- 1 January 2009
- Published by Springer Nature in Indian Journal of Gastroenterology
- Vol. 28 (1) , 24-27
CA 19-9 to differentiate benign and malignant masses in chronic pancreatitis: is there any benefit?
Background The role of the tumor marker CA 19-9 in differentiating benign from malignant masses in chronic pancreatitis has not been extensively studied. Aim This study aims at assessing the accuracy of CA 19-9 in differentiating inflammatory head masses in chronic pancreatitis from superimposed carcinomas on chronic pancreatitis. Methods The data of 84 consecutive patients who had mass lesions in chronic pancreatitis were analyzed to determine the sensitivity, specificity and predictive values at cut-off values of 37, 100, 200 and 300 U/mL. Receiver operating characteristic (ROC) curves were used to assess the sensitivity and specificity. Results There were 50 benign masses and 34 malignancies. The overall sensitivity and specificity of CA 19-9 for cancer was 68% and 70%, respectively. There was a higher positivity of CA 19-9 in cancers than in benign masses (23/34; 68% versus 15/50; 30%, P<0.01) with cut-off values of 37 U/mL. Higher positivity rates were obtained in cancers using other cut-off values such as 100, 200 and 300 U/mL. Values over 300 U/mL were 100% specific for malignancy, but occurred in only 5 (of whom had distant metastases) of 34 patients. Conclusion CA 19-9 level in excess of 300 U/mL in mass lesions in chronic pancreatitis was always indicative of malignancy.
- 8 February 2008
- Vol. 20 (5) , 243-4
Early pancreatic cancer: are we doing enough?
- 28 September 2007
- Vol. 28 (1) , 35-6
Intussusception due to ileal metastases from renal cell carcinoma.
Small bowel secondaries from renal cell carcinoma are rare. Patients usually present with features of intestinal obstruction or GI bleeding. Management should be aggressive since metastasectomy can improve the quality of life and survival.
- 28 September 2007
- Vol. 28 (1) , 35-6
Intussusception due to ileal metastases from renal cell carcinoma.
Small bowel secondaries from renal cell carcinoma are rare. Patients usually present with features of intestinal obstruction or GI bleeding. Management should be aggressive since metastasectomy can improve the quality of life and survival.
- 21 August 2007
- Vol. 26 (3) , 139-40
Intraductal papillary mucinous neoplasm in tropical chronic pancreatitis.
We report a 56-year-old man with chronic calcifying pancreatitis of the tropics (tropical calcific pancreatitis) who had been asymptomatic and on follow up developed a pancreatic mass that was identified as intraductal papillary mucinous neoplasm. He has been asymptomatic after distal pancreatectomy.
- 21 August 2007
- Vol. 26 (3) , 139-40
Intraductal papillary mucinous neoplasm in tropical chronic pancreatitis.
We report a 56-year-old man with chronic calcifying pancreatitis of the tropics (tropical calcific pancreatitis) who had been asymptomatic and on follow up developed a pancreatic mass that was identified as intraductal papillary mucinous neoplasm. He has been asymptomatic after distal pancreatectomy.
- 1 November 2006
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 244 (5) , 835-836
Extent of Mesorectal Tumor Invasion as a Prognostic Factor After Curative Surgery for T3 Rectal Cancer Patients
- 1 November 2006
- Published by Wolters Kluwer Health in Annals of Surgery
- Vol. 244 (5) , 835-836
Extent of Mesorectal Tumor Invasion as a Prognostic Factor After Curative Surgery for T3 Rectal Cancer Patients